deltatrials
Completed PHASE1 NCT00410982

Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies

Gemcitabine Combined With Busulfan and Melphalan, With Hematopoietic Cell Transplantation, for Patients With Poor-prognosis Advanced Lymphoid Malignancies

Sponsor: M.D. Anderson Cancer Center

Conditions Leukemia Lymphoma Myeloma
Interventions Busulfan Gemcitabine Hematopoietic Cell Transplantation Melphalan Palifermin Rituximab for Patients with B-Cell Malignancies
Updated 5 times since 2017 Last updated: Jun 1, 2016 Started: Dec 31, 2006 Primary completion: Sep 30, 2012 Completion: Sep 30, 2012

This PHASE1 trial investigates Leukemia and Lymphoma and is currently completed. M.D. Anderson Cancer Center leads this study, which shows 5 recorded versions since 2006 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1

    First recorded

Dec 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • M.D. Anderson Cancer Center
Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Houston, United States